Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice

International Journal of Antimicrobial Agents

Volumn 39, Issue 4, 2012, Pages 326-331

  Godinho, Joseane Lima Prado ^a   Simas Rodrigues, Cíntia ^a   Silva, Rosane ^a   Ürmenyi, Turán Peter ^a   De Souza, Wanderley ^a,b   Rodrigues, Juliany Cola Fernandes ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

Chemotherapy; Leishmania amazonensis; Miltefosine

Indexed keywords

MEGLUMINE ANTIMONATE; MILTEFOSINE; PROTOZOAL DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; LEISHMANIASIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANIMALS; ANTIPROTOZOAL AGENTS; AZURE STAINS; DNA, PROTOZOAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MEGLUMINE; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS; PARASITE LOAD; PHOSPHORYLCHOLINE; TIME FACTORS; ULCER;

EID: 84858280392     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.11.008     Document Type: Article

References (30)

1. Murray HW, Berman JD, Davies CR. Advances in leishmaniasis. Lancet 2005;366:1561-77. (Pubitemid 41540115)
2. Barral A, Pedral-Sampaio D, Grimaldi Jr G, Momen H, McMahon-Pratt D, de Jesus AM, et al. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg 1991;44:536-46.
3. Lainson R, Shaw JJ, Silveira FT, de Souza AAA, Braga RR, Ishikawa EAY. The dermal leishmaniases of Brazil, with special reference to the eco-epidemiology of the disease in Amazonia. Mem Inst Oswaldo Cruz 1994;89:435-43.
4. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006;19:111-26. (Pubitemid 43157649)
5. Runge MH, Andreesen R, Pfleiderer A, Munder PG. Destruction of human solid tumors by alkyl lysophospholipids. J Natl Cancer Inst 1980;64:1301-6. (Pubitemid 10109721)
6. Achterberg V, Gercken G. Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes. Mol Biochem Parasitol 1987;23:117-22. (Pubitemid 17041361)
7. Croft SL, Neal RA, Pendergast W, Chau JH. The activity of alkyl phosphorylcholines and related derivates against Leishmania donovani. Biochem Pharmacol 1987;36:2633-6. (Pubitemid 17102920)
8. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996;38:1041-7. (Pubitemid 27073283)
9. 3 (edelfosine) and amphotericin B. Acta Trop 2002;81:151-7.
10. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992;36:1630-4.
11. Morais-Teixeira E, Damasceno QS, Galuppo MK, Romanha AJ, Rabello A. The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil. Mem Inst Oswaldo Cruz 2011;106:475-8.
12. Berman JJ. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol 2008;4:1209-16.
13. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001;33:e57-61.
14. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 2004;38:1266-72. (Pubitemid 38608569)
15. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007;44:350-6. (Pubitemid 46147616)
16. Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008;78:210-1. (Pubitemid 351844550)
17. Soto J, Rea J, Balderrama M, Toledo J, Valda L, Ardiles J, et al. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 2009;81: 387-9.
18. Soto J, Berman JD. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 2006;100(Suppl. 1):S34-40. (Pubitemid 44490170)
19. Vélez I, López L, Sánchez X, Mestra L, Rojas C, Rodríguez E. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 2010;83:351-6.
20. Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT, Schriefer A, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010;4:1-6.
21. Chrusciak-Talhari A, Dietze R, Chrusciak-Talhari C, da Silva RM, Gadelha Yamashita EP, de Oliveira Penna G, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011;84:255-60.
22. Andrade HM, Toledo VP, Pinheiro MB, Guimarães TM, Oliveira NC, Castro JA, et al. Evaluation of miltefosine for the treatment of dogs naturally infected with L. infantum (=L. chagasi) in Brazil. Vet Parasitol 2011;181: 83-90.
23. Ganguly NK. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. The potential impact of miltefosine on visceral leishmaniasis in India. TDR News 2002;68:2.
24. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 2011;118:87-96.
25. Cummings KL, Tarleton RL. Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol 2003;129:53-9. (Pubitemid 36703222)
26. Aguiar MG, Pereira AMM, Fernandes AP, Ferreira LAM. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis. Antimicrob Agents Chemother 2010;54: 4699-704.
27. Aguiar MG, Silva DL, Nunan FA, Nunam EA, Fernandes AP, Ferreira LAM. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burden. J Antimicrob Chemother 2009;64:1234-40.
28. Serrano-Martín X, Payares G, de Lucca M, Martinez JC, Mendoza-León A, Benaim G. Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob Agents Chemother 2009;53: 5108-13.
29. Leon W, Fouts DL, Manning J. Sequence arrangement of the 16S and 26S rRNA genes in the pathogenic haemoflagellate Leishmania donovani. Nucleic Acids Res 1978;2:491-504. (Pubitemid 8279051)
30. Conlon I, Raff M. Differences in the way a mammalian cell and yeast cells coordinate cell growth and cell-cycle progression. J Biol 2003;2:7.